id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0369-0006,FDA,FDA-2025-E-0369,Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T20:09:40Z,2026-02976,1,0,09000064b91a72ba
FDA-2025-E-0369-0005,FDA,FDA-2025-E-0369,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T20:24:16Z,,0,0,09000064b90aa0ca
FDA-2025-E-0369-0004,FDA,FDA-2025-E-0369,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:22:58Z,,0,0,09000064b9069bba
FDA-2025-E-0369-0003,FDA,FDA-2025-E-0369,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-26T04:00:00Z,2025,9,2025-09-26T04:00:00Z,,2025-11-05T17:49:13Z,,0,0,09000064b8fe0d21
FDA-2025-E-0369-0002,FDA,FDA-2025-E-0369,Patent Extension Application from Polsinelli PC (on behalf of National Taiwan University),Other,Application,2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:33:24Z,,0,0,090000648691b896
FDA-2025-E-0369-0001,FDA,FDA-2025-E-0369,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:33:16Z,,0,0,090000648691b894